Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Completed 34Terminated 4Unknown 3Active not recruiting 3Recruiting 2Withdrawn 1

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 4Polycystic Ovary Syndrome 2Hyperandrogenism 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Flutamide × Clear all
NCT00651326 2023-08-04

DART

Canadian Cancer Trials Group

Phase 3 Terminated
48 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003645 2020-04-28

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

M.D. Anderson Cancer Center

Phase 3 Terminated
64 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT00512668 2013-01-07

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
24 enrolled
Genitourinary

Prostatic Neoplasms

NCT00388804 2012-08-08

External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer

M.D. Anderson Cancer Center

Phase 3 Terminated
39 enrolled 3 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡